Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report

Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.